GRI_OUT_1 [2025-04-01 09:38:34 -0400] 2171 Bytes | 619 tokens | Cum: 619 tkns (7.74% of 8k)
==========================================================================

We need a winner today and it's already 9:38:33 AM on Tue Apr 01, 2025 -0400 ... So let's find out if GRI Bio (GRI) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 7.79 up from 3.2. Is there something here we can get excited about? Help me analyze.

Here's the first list of news for GRI Bio:

C1 - Today 09:00AM - GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ( IPF )
C2 - Mar-31-25 08:00AM - GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
C3 - Mar-18-25 09:05AM - GRI Bio Participates in a Virtual Investor CEO Connect Segment
C4 - Mar-17-25 08:05AM - GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ( IPF )
C5 - Mar-11-25 08:35AM - GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule
C6 - Feb-19-25 04:05PM - GRI Bio Announces Reverse Stock Split
C7 - Feb-19-25 04:05PM 09:00AM - GRI Bio, Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference
C8 - Dec-23-24 09:00AM - GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on GRI Bio (GRI)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

GRI_OUT_3 [2025-04-01 09:38:40 -0400] 1099 Bytes | 334 tokens | Cum: 955 tkns (11.94% of 8k)
==========================================================================

Showing C1 (chunk 1 of 13): C1:
**GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ( IPF )**
Date: Today 09:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/04/01/3053442/0/en/GRI-Bio-Reports-Encouraging-Interim-2-Week-Safety-Results-from-Ongoing-Phase-2a-Study-of-GRI-0621-in-Idiopathic-Pulmonary-Fibrosis-IPF.html

April 01, 2025 09:00 ET| Source:GRI Bio, Inc.GRI Bio, Inc.

The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data reviewed

Interim results demonstrate GRI-0621 to be safe and well-tolerated in the first 12 patients evaluated

Interim biomarker data on track for Q2 2025 and topline results expected Q3 2025

Currently available treatments for IPF are limited to only two approved drugs that come with signi

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GRI_OUT_5 [2025-04-01 09:38:41 -0400] 1017 Bytes | 278 tokens | Cum: 1362 tkns (17.03% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T13:24:48Z - Empowering Global Users, Global Assets Releases AI Intelligent Trading System Technical Whitepaper...
A2 - 2025-04-01T13:25:42Z - GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in...
A3 - 2025-03-31T12:08:12Z - GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and ...
A4 - 2025-03-31T12:08:09Z - Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site...
A5 - 2025-03-31T12:07:05Z - GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and ...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

GRI_OUT_7 [2025-04-01 09:38:41 -0400] 1098 Bytes | 290 tokens | Cum: 1654 tkns (20.67% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**Empowering Global Users, Global Assets Releases AI Intelligent Trading System Technical Whitepaper**Date: 2025-04-01Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/04/01/tmt-newswire/globenewswire/empowering-global-users-global-assets-releases-ai-intelligent-trading-system-technical-whitepaper/2084418GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")

New York, April 01, 2025 (GLOBE NEWSWIRE) --

With the rapid development of financial technology, intelligent trading and decentralized finance (DeFi) are increasingly becoming important components of the financial market. In this trend, Global Assets proudly announces the release of its AI intelligent trading system technical whitepaper, aimed at creating an efficient, secure

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GRI_OUT_9 [2025-04-01 09:38:42 -0400] 1031 Bytes | 327 tokens | Cum: 1983 tkns (24.79% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-13T13:00:00Z - Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
B2 - 2024-12-23T14:00:00Z - GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
B3 - 2024-10-21T21:35:00Z - GRI Bio Announces Exercise of Warrants
B4 - 2024-07-15T13:07:14Z - GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series - GlobeNewswire
B5 - 2024-07-11T13:20:59Z - GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
B6 - 2024-07-04T09:27:26Z - Cystic Fibrosis Therapeutics Research Report 2024: A Global $15.42 Billion Market by 2032 from $7.07 Billion in 2023 ... - GlobeNewswire

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GRI_OUT_11 [2025-04-01 09:38:45 -0400] 725 Bytes | 195 tokens | Cum: 2180 tkns (27.25% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Windtree Announces the Addition of Leanne Kelly to Its Board of Directors**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/13/3008408/0/en/Windtree-Announces-the-Addition-of-Leanne-Kelly-to-Its-Board-of-Directors.htmlWindtree Therapeutics, a biotechnology company, announced the appointment of Leanne Kelly to its board of directors. Ms. Kelly has significant public company executive experience and will serve as an independent director and chair of the audit committee.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GRI_OUT_13 [2025-04-01 09:38:46 -0400] 1082 Bytes | 288 tokens | Cum: 2526 tkns (31.57% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-17 8-K Item 2.02 Results of Oper and Fin Cond.

On March 17, 2025, GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the year ended December 31, 2024, and provided a business update. A copy of this press release is furnished as Exh...

S2 - 2025-03-14 10-K Item 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER.

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and related notes beginning on page F-...

S10 - 2024-11-14 8-K Item 2.02 Results of Oper and Fin Cond.

On November 14, 2024, GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2024, and provided a business update. A copy of this press release is furnishe...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GRI_OUT_15 [2025-04-01 09:38:51 -0400] 1098 Bytes | 235 tokens | Cum: 2763 tkns (34.54% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
Item 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and related notes beginning on page F-1 of this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section entitled Item 1A. Risk Factors and Cautionary Note Regarding Forward-Looking Statements of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statement

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GRI_OUT_17 [2025-04-01 09:39:05 -0400] 5146 Bytes | 1543 tokens | Cum: 4425 tkns (55.31% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+---------------------+
| Volume: 0 | Perf Month: -59.60% | Option/Short: No / No | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+---------------------+
| Avg Volume: 17.40K | Perf Quarter: -76.01% | Short Float: 3.67% | ROE: -382.57% |
+--------------------+-----------------------+------------------------+---------------------+
| Rel Volume: 0.00 | Index: - | Short Ratio: 1.12 | ROI: -246.62% |
+--------------------+-----------------------+------------------------+---------------------+
| RSI (14): 25.92 | Market Cap: 1.68M | Short Interest: 0.02M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+---------------------+
| ATR (14): 1.10 | Shs Outstand: 0.53M | Beta: -1.72 | EPS Surprise: 8.22% |
+--------------------+-----------------------+------------------------+---------------------+
| SMA20: -49.26% | Shs Float: 0.53M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+---------------------+
| SMA50: -60.66% | Inst Own: 2.51% | Sales past 5Y: -20.00% | Earnings: Feb 26 |
+--------------------+-----------------------+------------------------+---------------------+
| SMA200: -77.02% | Insider Own: 0.05% | Employees: 4 | |
+--------------------+-----------------------+------------------------+---------------------+
| Perf Week: -60.30% | Insider Trans: 0.00% | Debt/Eq: 0.03 | |
+--------------------+-----------------------+------------------------+---------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: GRI Bio, Inc. (GRI) by Rongen Roelof (Unknown Title) on 2025-01-23
- Stock Option (Right to Buy): 30297 shares at $0.6857 (D)

Inside Trans: GRI Bio, Inc. (GRI) by Szekeres David Leslie (Unknown Title) on 2025-01-23
- Stock Option (Right to Buy): 51937 shares at $0.6857 (D)

Inside Trans: GRI Bio, Inc. (GRI) by Baker David Charles (Unknown Title) on 2025-01-23
- Stock Option (Right to Buy): 30297 shares at $0.6857 (D)

Inside Trans: GRI Bio, Inc. (GRI) by SIMPSON CAMILLA V (Unknown Title) on 2025-01-23
- Stock Option (Right to Buy): 30297 shares at $0.6857 (D)

Inside Trans: GRI Bio, Inc. (GRI) by Hertz Walter Marc (Chief Executive Officer) on 2025-01-23
- Stock Option (Right to Buy): 129730 shares at $0.6857 (D)

Inside Trans: GRI Bio, Inc. (GRI) by Chaturvedi Vipin (Chief Scientific Officer) on 2025-01-23
- Stock Option (Right to Buy): 43319 shares at $0.6857 (D)

Inside Trans: GRI Bio, Inc. (GRI) by Kelly Leanne (Chief Financial Officer) on 2025-01-23
- Stock Option (Right to Buy): 43319 shares at $0.6857 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -8207000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 9.51
Average Volume: 222056.05
30-Day High: 9.51
30-Day Low: 3.2

[Detailed Financials: TTM 2024]
- Total Assets: $5,739,000.0
- Total Liabilities: $1,707,000.0
- Total Equity: $4,032,000.0
- Current Assets: $5,615,000.0
- Current Liabilities: $1,636,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -55.21

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $0

[Detailed Financials: FY 2024]
- Total Assets: $5,739,000.0
- Total Liabilities: $1,707,000.0
- Total Equity: $4,032,000.0
- Current Assets: $5,615,000.0
- Current Liabilities: $1,636,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -55.21

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

GRI_OUT_19 [2025-04-01 09:39:10 -0400] 676 Bytes | 167 tokens | Cum: 4858 tkns (60.72% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

GRI_IN_21 [2025-04-01 09:39:10 -0400] 126 Bytes | 29 tokens | Cum: 4977 tkns (62.21% of 8k)
==========================================================================

====================================
[2025-04-01 09:39:10] # Analysis Completed
Elapsed Time: 37.01 seconds